China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategy

India's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. Indian firms must move beyond cost efficiency to capability leadership. This transition requires addressing gaps in advanced research and manufacturing. The next few years are crucial for India to secure its place in this evolving industry.